Publications & Presentations
A multicenter open-label study to assess the safety of a new formulation of BLP25 liposome vaccine in patients with unresectable stage III non-small-cell lung cancer »
Butts C, et. al,
Journal of Clinical Lung Cancer. 2010 Nov 1;11(6):391-5.
BLP25 liposome vaccine (L-BLP25) long-term safety results from phase IIb study of patients with stage IIIB and IV non-small-cell lung cancer (NSCLC) treated for 2 years or more
J Thorac Oncol. 2008 Jun;3(6 Suppl 2):S164-70. Review.
Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer »
Butts C, et. al,
Journal of Clinical Oncology. 2005 Sep 20;23(27):6674-81.
MUC1 Immunobiology: From Discovery to Clinical Applications
Vlad, et. al,
Advances in Immunology. 2004;82:249-93Journal of Clinical Oncology. 2005 Sep 20;23(27):6674-81.
return to top ^
|
